References
- Gobbi G, Bertani G, Pini A. Electrolyte, sporadic, metabolic, and endocrine disorders. In: Epilepsy: A Comprehensive Textbook. Engel J, Pedley TA (Eds). Lippincott–Raven, Philadelphia, PA, USA, 2605–2627 (1998).
- Israni IK, Kasbekar N, Haynes K et al. Use of antiepileptic drugs in patients with kidney disease. Semin. Dial.19, 408–416 (2006).
- US Renal Data System, USRDS 2011. 2011 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease In The United States. NIH, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, USA (2011).
- National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification and stratification. Am. J. Kidney Dis.39, S1–S266 (2002).
- Aymanns C, Keller F, Maus S et al. Review on pharmacokinetics and pharmacodynamics and the aging kidney. Clin. J. Am. Soc. Nephrol.5, 314–327 (2010).
- Verbeeck RK, Musuamba FT. Pharmacokinetics and dosage adjustment in patients with renal dysfunction. Eur. J. Clin. Pharmacol.65, 757–773 (2009).
- Olyaei AJ, Steffl JL. A quantitative approach to drug dosing in chronic kidney disease. Blood Purif.31, 138–145 (2011).
- Cervelli MJ, Russ GR. Principles of drug therapy, dosing, and prescribing in chronic kidney disease and renal replacement therapy. In: Comprehensive Clinical Nephrology. Floege, J, Johnson RJ, Feehally J (Eds). Elsevier Saunders, MO, USA, 871–893 (2010).
- Grant SM, Heel RC. Vigabatrin: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in epilepsy and disorders of motor and anxiety progressing to extreme aggression. Drugs41, 889–926 (1991).
- Jacqz-Aigrain E, Guillonneau M, Rey E et al. Pharmacokinetics of the S(+) and R(-) enantiomers of vigabatrin during chronic dosing in a patient with renal failure. Br. J. Clin. Pharmacol.44, 183–185 (1997).
- Perucca E, Cloyd J, Critchley D et al. Rufinamide: clinical pharmacokinetics and concentration-response relationships in patients with epilepsy. Epilepsia49(7), 1123–1141 (2008).
- Beyreuther B, Freitag J, Heers C et al. Lacosamide: a review of preclinical properties. CNS Drug Rev.13, 21–42 (2007).
- VIMPAT®, package insert. UCB, Smyrna, GA, USA.
- Bockbrader HN, Radulovic LL, Posvar EL et al. Clinical pharmacokinetics of pregabalin in healthy volunteers. J. Clin. Pharmacol.50(8), 941–950 (2010).
- Edward J. Randinitis EL. Pharmacokinetics of pregabalin in subjects with various degrees of renal function. J. Clin. Pharmacol.43(3), 277–283 (2003).
- Weisenberg J, Wong M. Profile of ezogabine (retigabine) and its potential as an adjunctive treatment for patients with partial-onset seizures. Neuropsychiatr. Dis. Treat.7, 409–414 (2011).
- Shin PG, Loewen G, Mansbach T et al. Effects of renal impairment on retigabine pharmacokinetics. Presented at: 62nd Annual American Epilepsy Society. Seattle, WA, USA, 5–9 December 2008 (Abstract 1.265).
- Trobalt®, package insert. GlaxoSmithKline, Stockley Park West, Uxbridge, Middlesex, UK.
- Maia J, Almeida L, Falcao A et al. Effects of renal impairment on the pharmacokinetics of eslicarbazepine. Int. J. Clin. Pharm. Ther.46, 119–130 (2008).
- Perucca E, Elger C, Halasz P et al. Pharmacokinetics of eslicarbazepine acetate at steady-state in adults with partial-onset seizures. Epilepsy Res.96(1–2), 132–918 (2011).
- Elger C, Bialer M, Cramer JA et al. Eslicarbazepine acetate: a double-blind, add-on, placebo-controlled exploratory trial in adult patients with partial-onset seizures. Epilepsia48(3), 497–504 (2007).
- Almeida L, Minciu I, Nunes T et al. Pharmacokinetics, efficacy, and tolerability of eslicarbazepine acetate in children and adolescents with epilepsy. J. Clin. Pharmacol.48, 966–977 (2008).
- Bestha DP. Brivaracetam SV2A ligand antiepileptic drug. Drugs Fut.35(3), 165–172 (2010).
- Sargentini-Maier ML, Rolan P, Connell J et al. The pharmacokinetics, CNS pharmacodynamics and adverse event profile of brivaracetam after single increasing oral doses in healthy males. Br. J. Clin. Pharmacol.63(6), 680–688 (2007).
- Hanada T, Hashizume Y, Tokuhara N et al. Perampanel: a novel, orally active, noncompetitive AMPA-receptor antagonist that reduces seizure activity in rodent models of epilepsy. Epilepsia52(7), 1331–1340 (2011).
- Hanks GW. Clobazam Pharmacological and therapeutic profile. Br. J. Clin. Pharmacol.7(1), S151–S155 (1979).
- Walzer M, Bekersky I, Beconi M et al. Effect of renal impairment on pharmacokinetics of clobazam. J. Clin. Pharmacol.50(9), 1058–1095 (2010).
- Roberts GW, Zoanetti GD. Clobazam and N-desmethylclobazam serum concentrations in endstage renal failure and hemodialysis. Ann. Pharmacother.28(7–8), 966–967 (1994).